From a clinical standpoint, although the prognostic/predictive role of HSP90 expression in HER2+ breast cancer remains ambiguous, further studies are warranted, especially in the settings of hormonal maintenance in patients co-expressing HER2 and ER as well as new HER2-targeted ADCs. This evidence concerns the gene ESR1 and breast cancer.